Neuraxpharm Australia Germany United Kingdom United States of America

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

[Accessed 19 June 2025.]Australian Government Department of Health, Disability and Ageing. Pharmaceutical Benefits Advisory Committee Meeting Outcomes. May 2025. [Accessed 20 June 2025] https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-05/pbac-web-outcomes-05-2025.pdfIn territories outside the United States (US), Canada, Mexico, and excluding certain Asian countries previously partnered, following the ex-US commercialisation agreement between TG Therapeutics and Neuraxpharm announced August 2023. https://www.neuraxpharm.com/news/tg-therapeutics-and-neuraxpharm-announce-ex-us-commercialization-agreement-for-briumvi-ublituximab-xiiy/European Medicines Agency (EMA). BRIUMVI (Ublituximab) Summary of Product Characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/briumvi [Accessed 25 June 2025.]Steinman L et al, N Eng J Med 2022; 387: 704-714, Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis https://www.nejm.org/doi/full/10.1056/NEJMoa2201904

View original content:https://www.prnewswire.co.uk/news-releases/neuraxpharm-continues-international-expansion-with-launch-of-neuraxpharm-australia-302509677.html